Diagnostics (Dec 2022)

Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients

  • Dolores Escudero,
  • Jonathan Fernández-Suarez,
  • Lorena Forcelledo,
  • Salvador Balboa,
  • Javier Fernández,
  • Ivan Astola,
  • Brigida Quindos,
  • Rainer Campos,
  • Fernando Vázquez,
  • José Antonio Boga

DOI
https://doi.org/10.3390/diagnostics12123134
Journal volume & issue
Vol. 12, no. 12
p. 3134

Abstract

Read online

Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Intensive Care Unit (ICU), detecting 78 pathogens in 59 (41%) samples. The molecular panel was evaluated by using the conventional culture (CC) as comparator, which isolated 42 pathogens in 40 (27.7%) samples. The overall percentage of agreement was 82.6%. Values of sensitivity (93%), specificity (62%), positive predictive value (50%), and negative predictive value (96%) were obtained. The mean time elapsed from sample extraction to modification of antibiotic treatment was 7.6 h. A change in antimicrobial treatment after the FAPP+ results was performed in 27% of patients. The FAPP+ is a highly sensitive diagnostic method that can be used to significantly reduce diagnostic time and that allows an early optimization of antimicrobial treatment.

Keywords